Heart failure & cardiomyopathies
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT Heart Failure (HF))-TIMI 68 Trial
Authors' conclusion
This is the first cardiovascular outcomes trial designed specifically to evaluate the efficacy and safety of in-hospital initiation of dapagliflozin in patients hospitalized for the management of acute HF.
Study context
- Population
- Patients hospitalised for acute HF, irrespective of LVEF, T2DM status or HF chronicity (de novo and worsening chronic HF)
- Participants
- 2,401 patients
- Comparison
- Dapagliflozin vs placebo, initiated in hospital
- Primary endpoint
- Time to first CV death or worsening HF (worsening HF during index admission, rehospitalisation for worsening HF, or urgent HF visit)
Methodological detailsdesign paper, international, double-blind, placebo-controlled, Blinded treatment for 2 months
- Design paper
- International
- Double-blind
- Placebo-controlled
- Blinded treatment for 2 months
Further findings
Key safety endpoints
- Symptomatic hypotension and worsening kidney function (planned; no results reported)
Original publication
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial. JACC Heart Fail. doi:10.
Summarised from the published abstract; every number is checked against it